Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05131984 · ClinicalTrials.gov registry record
Ocrelizumab Access by Socio-Economic Status
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 800
- Enrollment target
NCT05131984: Completed study, sponsored by Brigham and Women's Hospital.
NCT05131984 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 800 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05131984 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 800 participants
- Enrollment target
Study Summary
The primary aim of this project is to determine whether there are differences in access to, efficacy and tolerability of Ocrelizumab in men and women of different racial and ethnic origins and socio-economic backgrounds with RRMS and PPMS in two large academic MS Centers with a high volume of patients on Ocrelizumab. The study is a retrospective analysis of multiple sclerosis patients cared for at Brigham and Women's Hospital and Boston Medical Center who were treated with Ocrelizumab during the 4 year study period.
Primary Outcome
Time from diagnosis to Ocrelizumab treatment initiation in men and women of different racial and ethnic origins and socio-economic backgrounds with RRMS and PPMS.
Interventions
- DRUG Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2023-07-01 |
What the finished NCT05131984 record still lists
NCT05131984 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT05131984 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05131984 about?
NCT05131984 is a clinical study titled "Ocrelizumab Access by Socio-Economic Status". The primary aim of this project is to determine whether there are differences in access to, efficacy and tolerability of Ocrelizumab in men and women of different racial and ethnic origins and socio-economic backgrounds with RRMS and PPMS in two large academic MS Centers with a high volume of patien...
What is the current status of trial NCT05131984?
This trial is currently completed. The enrollment target is 800 participants. The study started on 2021-11-18. Estimated completion is 2023-07-01.
What interventions are being tested in trial NCT05131984?
The interventions under investigation include: Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT05131984?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI